Recycling side-effects into clinical markers for drug repositioning
被引:31
|
作者:
Duran-Frigola, Miquel
论文数: 0引用数: 0
h-index: 0
机构:
Inst Res Biomed IRB Barcelona, Joint IRB BSC Program Computat Biol, Barcelona 08028, SpainInst Res Biomed IRB Barcelona, Joint IRB BSC Program Computat Biol, Barcelona 08028, Spain
Duran-Frigola, Miquel
[1
]
Aloy, Patrick
论文数: 0引用数: 0
h-index: 0
机构:
Inst Res Biomed IRB Barcelona, Joint IRB BSC Program Computat Biol, Barcelona 08028, Spain
ICREA, Barcelona 08010, SpainInst Res Biomed IRB Barcelona, Joint IRB BSC Program Computat Biol, Barcelona 08028, Spain
Aloy, Patrick
[1
,2
]
机构:
[1] Inst Res Biomed IRB Barcelona, Joint IRB BSC Program Computat Biol, Barcelona 08028, Spain
[2] ICREA, Barcelona 08010, Spain
来源:
GENOME MEDICINE
|
2012年
/
4卷
关键词:
Side effects;
drug repositioning;
polypharmacology;
mechanism of action;
D O I:
10.1186/gm302
中图分类号:
Q3 [遗传学];
学科分类号:
071007 ;
090102 ;
摘要:
Side-effects are the unintended consequence of therapeutic treatments, but they can also be seen as valuable read-outs of drug effects in humans; these effects are difficult to infer or predict from pre-clinical models. Indeed, some studies suggest that drugs with similar side-effect profiles may also share therapeutic properties through related mechanisms of action. A recent publication exploits this concept to systematically investigate new indications for already marketed drugs, and presents a strategy to get the most out of the tiny portion of chemicals that have proved to be effective and safe.